News

Novo Nordisk cuts forecasts, shares rise ahead of FDA ban on Wegovy copycats
Pedersen and Maggie Fick COPENHAGEN/LONDON (Reuters) - Obesity drugmaker Novo Nordisk cut its sales forecasts on Wednesday ...
NBC Los Angeles4h
Novo Nordisk cuts 2025 guidance as drug copycats hit Wegovy sales, posts first-quarter profit beat
Novo Nordisk on Wednesday reported a better-than-expected rise in net profit but lowered its full-year sales growth forecast.
NJBIZ13h
Novo Nordisk seeks FDA approval for Wegovy weight loss pill
Novo Nordisk’s oral Wegovy pill for chronic weight loss is under FDA review. If approved, it would be the first oral GLP-1 ...
Novo Nordisk's CFO sceptical Trump executive order on drug manufacturing can cut timelines
Obesity drugmaker Novo Nordisk's CFO said on Wednesday he was sceptical that U.S. President Donald Trump's executive order to ...
EconoTimes4h
Novo Nordisk Lowers 2025 Outlook Despite Q1 Profit Beat on Strong GLP-1 Sales
Novo Nordisk (NYSE:NVO) trimmed its full-year 2025 sales and profit forecast on Wednesday, citing weaker-than-expected U.S.
Novo Nordisk: Q1 Earnings Snapshot
BAGSVAERD, Denmark (AP) — BAGSVAERD, Denmark (AP) — Novo Nordisk A/S (NVO) on Wednesday reported first-quarter earnings of $4.09 billion. The Bagsvaerd, Denmark-based company said it had profit of 92 ...
Top Analyst Reports for Novo Nordisk, Honeywell & American Tower
Today's Research Daily features new research reports on 16 major stocks, including Novo Nordisk A/S (NVO), Honeywell ...
The Manila Times22h
Novo Nordisk A/S: ECO 2025 - Novo Nordisk semaglutide data shows new health benefits across serious chronic diseases
Semaglutide is marketed under the brand names Wegovy ® (once-weekly semaglutide 2.4 mg injection), Ozempic ® (once-weekly ...